Search PubMed⌕ Search

PubMed · 11461803

Monotherapy trials: sequential design.

Abstract

In a sequential clinical trial, the accumulating data are subjected to a series of interim analyses, each of which involves a comparison of the treatments under study in respect of the primary efficacy criterion. The trial is stopped as soon as it is evident that one treatment is superior to the other, or that no such difference is going to be found. The stopping rule is devised to ensure that the required significance level and power are achieved and that valid statistical inference can be drawn at the end of the study. The methodology will be presented by means of a case study. This is the SEReNE study, which was completed last year and compared remacemide with carbamazepine in the treatment of newly diagnosed epilepsy. The study employed a double triangular test: an efficient form of sequential design for the comparison of two active treatments. The primary efficacy response was time from randomisation to the first seizure following dose titration. Details will be given of the stopping rule employed, the number of patients forecasted, the progress of the trial and its final analysis. The procedure adopted will be reviewed, and its suitability for future trials assessed.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

J Whitehead. 2001. Monotherapy trials: sequential design.. https://doi.org/10.1016/s0920-1211(01)00224-8. https://searchpubmed.org/record/pubmed%3A11461803/monotherapy-trials-sequential-design

Citations retain the original authors and DOI and include this site’s record URL. If this discovery service contributed to your research, you can also cite Search PubMed by Indiciae: BibTeX · RIS.

KEEP EXPLORING

Related citations

A double-blind placebo-controlled trial of zonisamide (zonegran) in the treatment of essential tremor.

Medical therapy for essential tremor (ET), a common movement disorder, is often inadequate. We performed a double-blind placebo-controlled randomized trial to evaluate the efficacy and tolerability of zonisamide (ZNS), an antiepileptic agent, in treating ET. Twenty patients (mean age, 60 +/- 15 years) with ET were randomized to receive ZNS or placebo. ZNS was initiated at a dosage of 100 mg/day and escalated to 200 mg/day at day 14. Patients were evaluated by accelerometry and the Fahn-Tolosa-Marin (FTM) rating scale at baseline and days 14 and 28, as well as the Clinical Global Impression (CGI-C) scale at day 28. At endpoint, subjects assigned to ZNS were taking a mean dosage of 160 +/- 50 mg/day. There were no significant improvements in the FTM total score or its subsections. Tremor amplitude as assessed by accelerometry significantly improved in the ZNS group compared to the placebo group at endpoint relative to baseline (-0.50 +/- 0.72 vs. 0.30 +/- 0.79 m/s(2); P = 0.03). On the CGI-C, 60% (n = 6) of patients in the ZNS group felt that their tremor was unchanged, while the remaining patients felt that their tremor was "minimally improved." Thirty percent (n = 3) of patients taking ZNS discontinued the study due to side effects (fatigue, headache, paresthesias) while taking 100 mg per day. ZNS did not provide significant improvements in clinical rating scales at study endpoint compared to placebo and was only modestly well tolerated. ZNS was effective in reducing tremor amplitude as measured by accelerometry.

Anticonvulsants↗